Tiziana Life Sciences Ltd

Tiziana Life Sciences is a Nasdaq-listed biotechnology company incorporated in Bermuda and headquartered in London that develops therapies targeting neurodegenerative and lung diseases. The company's primary focus is immunology, where it is advancing Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody in development for multiple autoimmune and inflammatory conditions including Crohn's disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, rheumatoid arthritis, psoriasis, and graft versus host disease. The company is also developing TZLS-501, a fully human monoclonal antibody targeting the IL-6 receptor for inflammatory and oncology indications.

The company operates with a small team of nine full-time employees and maintains its principal operations in the United States, where clinical development activities are concentrated. As a preclinical and clinical-stage biotechnology firm, Tiziana Life Sciences does not generate material product revenues and operates primarily on a development and research basis. The company was founded in 1998 and has evolved from its origins into a focused immunology-driven organization, though detailed information regarding specific revenue streams or business segment composition is not publicly detailed.